

An Elsevier Indexed Journal

ISSN-2230-7346



Journal of Global Trends in Pharmaceutical Sciences

## STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF SIMULTANEOUS ESTIMATION OF CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM

## Ponna Venkatesh\*, R.V. Valli Kumari, S. Marakatham, Meruva Sathish Kumar

Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Dullapally, Hyderabad.

\*Corresponding author E-mail: ponnavenkatesh836@gmail.com

#### ARTICLE INFO

### Key Words

Ciprofloxacin, Fluocinolone, RP-HPLC




A simple, Accurate, precise method was developed for the simultaneous estimation of the Ciprofloxacin and Fluocinolone in ear drops. Chromatogram was run through Std Kromosil C18 250 x 4.6 mm, 5µ. Mobile phase containing Buffer 0.1% OPA (2.2ph): Acetonitrile taken in the ratio 55:45 was pumped through column at a flow rate of 0.9ml/min. Buffer used in this method was 0.1% OPA. Temperature was maintained at 30°C. Optimized wavelength selected was 246 nm. Retention time of Ciprofloxacin and Fluocinolone were found to be 2.290min and 2.901min. %RSD of the Ciprofloxacin and Fluocinolone were and found to be 0.2 and 0.2 respectively. %Recovery was obtained as 99.51% and 99.46% for Ciprofloxacin and Fluocinolone respectively. LOD, LOQ values obtained from regression equations of Ciprofloxacin and Fluocinolone were 0.12. 0.47 and 0.05, 0.14 respectively. Regression equation of Ciprofloxacin is v = 25741x + 1481., and y = 50539x + 785.5 of Fluocinolone. Retention times were decreased and run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.


ABSTRACT

## **INTRODUCTION**

Ciprofloxacin (1 - cyclopropyl -6 - fluoro - 4 - oxo - 7 - (piperazin -1 - yl) - 1, 4 - dihydroquinoline - 3 - 3carboxylic acid). Ciprofloxacin is a broad-spectrum antimicrobial carboxy fluoroquinoline. The germicidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, that area unit needed for microorganism replication, deoxyribonucleic acid transcription, repair, strand supercoiling repair, and recombination. Ciprofloxacin is an antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra-abdominal infections, certain type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth, in eye drops, or intravenously. Fluocinolone acetonide (1S, 2S, 4R, 8S, 9S, 11S, 12R, 13S, 19S) - 12, 19 difluoro – 11 – hydroxy – 8 - (2 – hydroxyl acetyl) - 6, 6, 9, 13 – tetramethyl - 5, 7 – dioxapentacyclo [10.8.0.0<sup>2, 9.04, 8.0<sup>13</sup>,</sup> <sup>18</sup>] icosa - 14, 17 - dien - 16 - one). A glucocorticoid derivative used topically inside the remedy of various pores and skin issues. It is also hired as a cream, gel, lotion, or ointment. It is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Fluocinolone reduces the swelling, itching, and redness that can occur in these types of conditions. The main aim of the present study is to develop an accurate, precise, sensitive, selective, reproducible and rapid analytical technique for cost effective estimation of Betamethasone, Gentamicin and Miconazole in combination. The objectives are to develop analytical method. Selecting the HPLC separation mode. Selecting/ optimizing the mobile phase. Selecting column for analysis. Selecting the appropriate detector systems. Selecting appropriate gradient/ isocratic medium.

## Fig 1: Ciprofloxacin & Fig 2: Fluocinolone Acetonide





## MATERIALS AND METHODS

**Materials and Instruments:** The following materials used were either AR/LR grade or the best possible Pharma grade available as supplied by the manufacturer or supplier without further purification or investigation. Drug Samples Were obtained from Spectrum pharma research solutions pvt. Ltd

## **METHODS:**

**Diluent:** primarily based up at the solubility of the medicine, diluent become decided on, Acetonitrile and Water taken in the ratio of 50:50.

Preparation of Standard stock solutions: Accurately weighed 15 mg of Ciprofloxacin, 1.25mg of Flucinolone and transferred to 50ml and 50ml individual volumetric flasks and 3/4 thof diluents was added to theseflaskand sonicated for 10 minutes. Flask were made up with diluents and labeled as Standard stock solution. 1ml from each stock solution was pipetted out and taken into a 10ml volumetric flask and made up with diluent. (30µg/ml Ciprofloxacin of and 2.5µg/ml ofFluocinolone)

**Preparation of Sample stock solutions:** A volume of ear drops (OTOVEL) equivalent to0.75 mg and 0.0625 mg of CIP and FLU respectively transferred into a 10ml volumetric flask,5mlofdiluentswasaddedandsonicatedf or25min,furtherthe volume wasmadeup with diluent and filtered by HPLC filters (75µg/ml of Ciprofloxacin and 6.25µg/ml of flucinolone).

**Preparation of Sample working solutions (100% solution):** 4ml of filtered sample stock solution was transferred to 10ml volumetric flask and made up with diluent. (30µg/ml of Ciprofloxacin and 2.5µg/ml of Flucinolone) **Preparation of buffer:** 0.1% OPA Buffer: 1ml of Conc Ortho Phosphoric acid was diluted to 1000ml with water.

# **RESULTS AND DISCUSSION**

**System suitability:** All the system suitability variables were within the range and satisfactory as per ICH guidelines. According to ICH guidelines plate count should be more than 2000, tailing factor should be less than 2 and resolution must be more than 2. All the system suitable parameters were passed and were within the limits.

**Specificity:** Retention times of Ciprofloxacin and Fluocinolone were 2.290min and 2.901 min respectively. We did not found and interfering peaks in blank and placebo at retention times of these drugs in this method. So this method was said to be specific.

## Accuracy:

**Preparation of Standard stock solutions:** Exactly weighed 15 mg of Ciprofloxacin, 1.25mg of flucinolone and transferred to 50ml and 50ml independent volumetric flasks and 3/4th of diluents become brought to those flask and sonicated for 10 mins. Flask were made up with diluents and categorised as widespread inventory answer.

**Preparation of 50% Spiked Solution:** 0.5ml of test stock arrangement was taken into a 10ml volumetric cup, to that 1.0ml from every standard stock arrangement was pipetted out, and made up to the stamp with diluent.

**Preparation of 100% Spiked Solution:** 1ml of test stock arrangement was taken into a 10ml volumetric cup, to that 1.0ml from every standard stock arrangement was pipetted out, and made up to the stamp with diluent. **Preparation of 150% Spiked Solution:** 1.5ml of test stock arrangement was taken into a 10ml volumetric cup, to that 1.0ml from every standard stock arrangement was pipetted out, and made up to the stamp with diluent.

## **Precision:**

**Preparation** of Standard stock solutions: Exactly weighed 15mg of Ciprofloxacin, 1.25mg of Flucinolone and transferred to 50ml and 50ml independent volumetric flasks and 75% of diluents was added to this flaskand sonicated for 10 minutes. Flask were made up with diluents and named as Standard stock arrangement. 1ml from each stock arrangement was pipetted out and taken into a 10ml volumetric flagon and made up with diluent. (100µg/ml Ciprofloxacin of and 50µg/ml of Fluocinolone)

## Linearity:

Preparation of Standard stock solutions: Accurately weighed 15 mg of Ciprofloxacin, 1.25mg of Flucinolone and transferred to 50ml and 50ml individual volumetric flasks and 3/4<sup>th</sup> of diluents was added to these flask and sonicated for 10 minutes. Flask were made up with diluents and labeled as Standard stock solution. 1ml from each stock solution was pipetted out and taken into a 10ml volumetric flask and made up with diluent. (30µg/ml Ciprofloxacin of and 2.5µg/ml of Fluocinolone)

**25% Standard solution:** 0.25ml each from two standard stock solutions was pipette out and made up to 10ml.

**50% Standard solution:** 0.5ml each from two standard stock solutions was pipette out and made up to 10ml.

**75% Standard solution:** 0.75ml each from two standard stock solutions was pipette out and made up to 10ml.

| S no | Ciprofloxacin |                    | Fluocinolone |         |                    |         |            |
|------|---------------|--------------------|--------------|---------|--------------------|---------|------------|
| Inj  | RT(min)       | USP Plate<br>Count | Tailing      | RT(min) | USP Plate<br>Count | Tailing | Resolution |
| 1    | 2.285         | 3418               | 1.41         | 2.889   | 4674               | 1.38    | 3.7        |
| 2    | 2.290         | 3480               | 1.47         | 2.901   | 5036               | 1.31    | 3.7        |
| 3    | 2.300         | 3493               | 1.39         | 2.907   | 4839               | 1.42    | 3.7        |
| 4    | 2.306         | 3463               | 1.49         | 2.909   | 4691               | 1.44    | 3.6        |
| 5    | 2.306         | 3548               | 1.44         | 2.916   | 5126               | 1.35    | 3.7        |
| 6    | 2.309         | 3663               | 1.44         | 2.916   | 5142               | 1.33    | 3.8        |

Table: 1. System suitability parameters for Ciprofloxacin and Fluocinolone




Fig 3. System suitability Chromatogram






Fig 5. Chromatogram of Placebo




Fig 6. Optimized Chromatogram

## Ponna Venkatesh et al, J. Global Trends Pharm Sci, 2018; 9(3): 5777- 5784

| %Level   | Amount Spiked | Amount recovered | % Recovery | Mean %Recovery   |
|----------|---------------|------------------|------------|------------------|
| 70 Level | (µg/mL)       | $(\mu g/mL)$     | % Recovery | Weall % Recovery |
|          | 15            | 14.97            | 99.81      |                  |
| 50%      | 15            | 14.96            | 99.74      |                  |
| 30%      | 15            | 14.92            | 99.46      |                  |
|          | 30            | 29.77            | 99.25      |                  |
| 1000/    | 30            | 29.85            | 99.49      |                  |
| 100%     | 30            | 29.87            | 99.55      |                  |
|          | 45            | 44.81            | 99.58      | 99.51%           |
| 150%     | 45            | 44.92            | 99.82      | ]                |
|          | 45            | 44.51            | 98.91      |                  |

## Table 2. Accuracy table of ciprofloxacin

Table 3. Accuracy table of flucinolone




Fig 7. Accuracy 50% Chromatogram of Ciprofloxacin and Fluocinolone




Fig 8. Accuracy 100% Chromatogram of Ciprofloxacin and Fluocinolone




Fig 9. Accuracy 150% Chromatogram of Ciprofloxacin and Fluocinolone

| S. No | Area of Ciprofloxacin | Area of fluocinolone |
|-------|-----------------------|----------------------|
| 1.    | 767458                | 130367               |
| 2.    | 776154                | 130241               |
| 3.    | 781720                | 130572               |
| 4.    | 777095                | 130576               |
| 5.    | 772878                | 131365               |
| 6.    | 773670                | 131038               |
| Mean  | 774829                | 130693               |
| S.D   | 4771.9                | 426.5                |
| %RSD  | 0.6                   | 0.3                  |

Table 4. System precision table of Ciprofloxacin and fluocinolone




Fig 10. System precision chromatogram





Fig 11. Intermediate precision Chromatogram

Table 6. Linearity table for Ciprofloxacin and Fluocinolone.

| Ciprof       | loxacin   | Fluocinolone |           |
|--------------|-----------|--------------|-----------|
| Conc (µg/mL) | Peak area | Conc (µg/mL) | Peak area |
| 0            | 0         | 0            | 0         |
| 7.5          | 191827    | 0.625        | 33546     |
| 15           | 387372    | 1.25         | 63627     |
| 22.5         | 592805    | 1.875        | 93999     |
| 30           | 764606    | 2.5          | 129428    |
| 37.5         | 971974    | 3.125        | 158949    |
| 45           | 1156053   | 3.75         | 189275    |








Fig 13. Calibration curve of Fluocinolone

| S.no | Condition                | %RSD of Ciprofloxacin | %RSD of Fluocinolone |
|------|--------------------------|-----------------------|----------------------|
| 1    | Flow rate (-) 0.8ml/min  | 0.3                   | 0.4                  |
| 2    | Flow rate (+) 1.1ml/min  | 0.5                   | 0.4                  |
| 3    | Mobile phase (-) 50B:50A | 0.5                   | 0.6                  |
| 4    | Mobile phase (+) 60B:40A | 0.7                   | 0.8                  |
| 5    | Temperature (-) 25°C     | 0.4                   | 0.3                  |
| 6    | Temperature (+) 35°C     | 1.0                   | 1.2                  |

Table 7. Robustness data for Ciprofloxacin and Fluocinolone.




Fig 14. Flow minus Chromatogram of Ciprofloxacin and Fluocinolone




Fig 15. Flow plus Chromatogram of Ciprofloxacin and Fluocinolone




Fig 16. Mobile phase minus Chromatogram of Ciprofloxacin and Fluocinolone




Fig 17. Mobile phase Plus Chromatogram of Ciprofloxacin and Fluocinolone




Fig 18. Temperature minus Chromatogram of Ciprofloxacin and Fluocinolone





Fig 19. Temperature plus Chromatogram of Ciprofloxacin and Fluocinolone

Table 8. Sensitivity table of Ciprofloxacin and Fluocinolone

| Molecule      | LOD(µg/mL) | LOQ(µg/mL) |
|---------------|------------|------------|
| Ciprofloxacin | 0.12       | 0.37       |
| Fluocinolone  | 0.05       | 0.14       |



# Fig 15. LOD Chromatogram of Standard





Fig 16. LOQ Chromatogram of of Standard


| S.no  | Standard Area | Sample area | % Assay |  |
|-------|---------------|-------------|---------|--|
| 1     | 767458        | 773813      | 99.67   |  |
| 2     | 776154        | 770138      | 99.20   |  |
| 3     | 781720        | 771719      | 99.40   |  |
| 4     | 777095        | 772912      | 99.55   |  |
| 5     | 772878        | 771957      | 99.43   |  |
| 6     | 773670        | 768714      | 99.01   |  |
| Avg   | 774829        | 771542      | 99.38   |  |
| Stdev | 4772.0        | 1855.1      | 0.2     |  |
| %RSD  | 0.6           | 0.2         | 0.2     |  |


## Table 9. Assay Data of Ciprofloxacin

## Table 10. Assay Data of Fluocinolone

| Tuble 101 Hisbuy Duta of Havemotone |               |             |         |  |
|-------------------------------------|---------------|-------------|---------|--|
| S. no                               | Standard Area | Sample area | % Assay |  |
| 1                                   | 130367        | 129905      | 99.20   |  |
| 2                                   | 130241        | 129997      | 99.27   |  |
| 3                                   | 130572        | 130088      | 99.34   |  |
| 4                                   | 130576        | 130269      | 99.48   |  |
| 5                                   | 131365        | 130625      | 99.75   |  |
| 6                                   | 131038        | 129913      | 99.20   |  |
| Avg                                 | 130693        | 130133      | 99.37   |  |
| Stdev                               | 426.5         | 276.2       | 0.2     |  |
| %RSD                                | 0.3           | 0.2         | 0.2     |  |










Fig 18. Chromatogram of working sample solution

**100% Standard solution:** 1.0ml each from two standard stock solutions was pipette out and made up to 10ml.

**125% Standard solution:** 1.25ml each from two standard stock solutions was pipette out and made up to 10ml.

**150% Standard solution:** 1.5ml each from two standard stock solutions was pipette out and made up to 10ml.

**Robustness:** Robustness conditions like flow minus (0.9ml/min), Flow plus (1.1ml/min), mobile phase minus, Mobile phase plus, Temperature minus (25°C) and temperature plus (35°C) was maintained and samples were injected in duplicate manner. System suitability parameters were not much affected and all the parameters were passed. %RSD was within the limit

**LOD sample Preparation:** 0.25ml each from two standard stock solutions was pipetted out and transferred to two separate 10ml volumetric flasks and

made up with diluents. From the above solutions 0.1ml each of ciprofloxacin, Fluocinolone, solutions respectively were transferred to 10ml volumetric flasks and made up with the same diluents

**LOQ sample Preparation:** 0.25ml each from two standard stock solutions was pipetted out and transferred to two separate 10ml volumetric flask and made up with diluent. From the above solutions 0.3ml each of Ciprofloxacin, fluocinolone, and solutions respectively were transferred to 10ml volumetric flasks and made up with the same diluent.

Assay: Arbor Pharmaceuticals Ltd. (OTOVEL), bearing the label claim ciprofloxacin 0.3% and fluocinolone acetonide 0.025%. Assay was performed with the above formulation. Average % Assay for Ciprofloxacin and Fluocinolone obtained was 99.38% and 99.37% respectively

#### CONCLUSION

А simple. Accurate, precise developed method was for the simultaneous estimation of the Ciprofloxacin and Fluocinolone in ear drops. Retention time of Ciprofloxacin and Fluocinolone were found to be 2.290in and 8.901min. %RSD of the Ciprofloxacin and Fluocinolone were and found to be 0.2 and 0.2 respectively. %Recovery was obtained as 99.61% and 99.46% for Ciprofloxacin and Fluocinolone respectively. LOD, LOQ values obtained from regression equations of Ciprofloxacin and Fluocinolone were 0.12, 0.37 and 0.05, 0.14 respectively. Regression equation of Ciprofloxacin is y = 25741x + 1481, and y = 50539x + 785.5of Fluocinolone. Retention times were decreased and that run time was decreased. so the method developed was simple and economical that can be adopted in regular **Ouality control test in Industries** 

#### REFERENCES

- R. G Chatwal, Anand K.S. High performance liquid chromatography. Instrumental methods of chemical analysis, 5<sup>th</sup> ed; Himalaya publishers: Mumbai, 2010; 2.570-2.629.
- B. K Sharma, High performance liquid chromatography. Instrumental methods of chemical analysis, 24<sup>th</sup> ed; Goel publishers: Meerut, 2005; 295-300.
- W.M. Dong HPLC Instrumentation and trends. Modern HPLC for practicing scientists. USA. 2006; 5-10, 78-110.
- 4. A. Skoog, DM *West*, FJ Holler, Fundamentals of Analytical Chemistry, 7th edition, Saunders College Publishing, Philadelphia, 1992, P.1-3.
- K. A Corners. Textbook of Pharmaceutical Analysis, A Wileyinter science Publication, 1st edition 1967, P.475-478.

- A.V Kasture., Wadodkar S.G., Mahadik K.R., More H.N. Textbook of Pharmaceutical Analysis – II, Published by Nirali Prakashan, 13th edition, 2005
- A.H. Beckett and StanlakeJ.B. Practical Pharmaceutical Chemistry, Part 2, CBS Publishers and Distributors; 4th edition.2002; P.157-174.
- R.L Snyder, kirklannd J.J, Glaijch L.J. Practical HPLC method development, 2<sup>nd</sup>ed; New York, 30-100 (1997);
- A. Satinder, Dong M.W, Method development and validation .Pharmaceutical analysis by HPLC, 15<sup>th</sup> ed; Newyork, 16-70( 2005);
- M.E Swartz, Ira krull, Analytical method development and validation, 1<sup>st</sup>ed; Marcel Dekker, New York, 17-80(2009);
- 11. British Pharmacopoeia, The Stationary Office, London(2005);
- International Conference on Harmonization. Q1A - (R2)
   Stability testing of New Drug Substances and Products., (2003);
- Indian Pharmacopoeia, Ministry of Health & Family Welfare, Government of India, New Delhi(1996);
- 14. The United States Pharmacopoeiathe National Formulary, United States Pharmacopoeial convention, Rockville (2007);
- 15. https://www.drugbank.ca/
- 16. https://www.drugbank.ca/drugs/DB 00591.
- 17. https://www.drugbank.ca/drugs/DB 00537.
- 18. "https://www.drugs.com/sfx/Flucino lone-side-effects.html".

- 19. https://www.scbt.com/scbt/product/ ciprofloxacin-hcl-93107-08-5
- 20. https://www.scbt.com/scbt/product/f luocinolone-807-38-5
- 21. Espinosa- Mansilla, Muñoz de la Peña A, González Gómez D. Cañada-Cañada FA et al., (2006) **HPLC** determination of ciprofloxacin, cloxacillin, and ibuprofen drugs in human urine samples. J Sep Sci. 2006: 29(13):1969-76.
- 22. A. Chmielewska, L. Konieczna, and H. Lamparczyk et al.,(2006) development of a reversed-phase HPLC method for analysis of fluocinolone acetonide in gel and ointment.actachromatographica, 16,2006.
- Scherer et al., Determination of Ciprofloxacin in Pharmaceutical Formulations Using HPLC Method with UV Detection. Indian J Pharm Sci. 2014 Nov-Dec; 76(6): 541–544.
- 24. Sani A. Emmanuel T. Alemika, Musa A. Sani and Mohammed Ilyas et al., High Performance Liquid Chromatography (HPLC) Method Development and Validation Indicating Assay for Ciprofloxacin Hydrochloride. Journal of Applied Pharmaceutical Science 01 (08); 2011:239-243.
- 25. Shihn- Sheng Wu, Chih-Yuan Chein, and Yen-Hsia Wen\* et al Analysis of Ciprofloxacin by a Simple High-Performance Liquid Chromatography Method. Journal of Chromatographic Science, Vol. 46, July2008.
- 26. Janis Vellaa, Francesca Busuttil et al., a simple hplc–uv method for the determination of ciprofloxacin in human plasma, Journal of

Chromatography B Volume 989, 1 May 2015, Pages80-85.

- 27. Syeda Kulsum, Rahul Reddy. M.Kanaka Durga1, M.Padmalatha1 et al., a simple and validated RP-HPLC method for the simultaneous estimation of tinidazole and in ciprofloxacin bulk and pharmaceutical dosage forms. Int. J. Res. Dev. Pharm. L. Sci. 2012-13, Vol. 2, No.1, pp238-243.
- 28. Mohsen Amini, Mahnaz Khanavi, Abbas Shafiee et al., Simple High-Performance Liquid Chromatographic Method for Determination of Ciprofloxacin in Human Plasma. Iranian Journal of Pharmaceutical Research (2004) 2:99-101.
- 29. Peikova, N. Zareva et al., RP-HPLC method for determination of ciprofloxacin in pharmaceutical dosage forms. Pharmacia, vol. 63, No.1/2016.
- 30. Bhargav Patel, Dharanant Borkhatariya, Mahesh Khodifad, Kuldip R Marwada et al.. development and validation of rpmethod for simultaneous hplc estimation of fluocinolone acetonide and miconazole nitrate inointment.